Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00970502

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation

Sponsor: Johnny Kao

Conditions Cancer of the Head Cancer of the Larynx Cancer of the Neck Cancer of the Pharynx Paranasal Sinus Neoplasms

Interventions erlotinib + celecoxib

Updated 6 times since 2017 Last updated: Feb 24, 2017 Started: Feb 28, 2007 Primary completion: Nov 30, 2010 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00970502, this PHASE1/PHASE2 trial focuses on Cancer of the Head and Cancer of the Larynx and remains completed. Sponsored by Johnny Kao, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnny Kao

Data source: Icahn School of Medicine at Mount Sinai

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States